Friess Associates’s Enzymotec Ltd ENZY Stock Holding History

Friess Associates’s Portfolio ENZY Stock Details ENZY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-122,500	Closed	-$2.7M	–	182
2014 Q1	$2.7M	Buy	+122,500	New	+$3.25M	0.21%	73

Other funds holding ENZY

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MCM

Matterhorn Capital Management San Antonio, Texas $151M AUM 14.71% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return

MACM

March Altus Capital Management Greenwich, Connecticut $16M AUM 18.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Friess Associates's ENZY Position: Q2 2014 in Review

Friess Associates sold out of Enzymotec Ltd (ENZY) in Q2 2014, closing a stake of 122,500 shares — an estimated $2.7M sold.

Friess Associates first reported a position in ENZY in Q1 2014 and held it in 1 quarter. The position peaked at $2.7M in Q1 2014. 25 funds tracked by Wall St. Rank hold ENZY as of Q2 2014.

Friess Associates reported no remaining Enzymotec Ltd position as of Q2 2014 after selling out during the quarter.
Friess Associates sold 122,500 Enzymotec Ltd shares in Q2 2014, an estimated $2.7M.
Friess Associates first reported a position in Enzymotec Ltd in Q1 2014 and held it in 1 quarter.
Friess Associates's Enzymotec Ltd position peaked at $2.7M in Q1 2014.
25 funds tracked by Wall St. Rank held Enzymotec Ltd as of Q2 2014.

Based on Friess Associates's 13F filing for Q2 2014, filed 14 Aug 2014.